Table 3.
Serological characteristics of the study subgroups at the time of enrolment.
| aPL Profile | Primary APS—Number of Positive Patients | Secondary APS—Number of Positive Patients |
|---|---|---|
| aCL | 1 | 4 |
| aβ2GPI | 4 | 8 |
| aPE | 4 | 8 |
| aPS | 1 | 5 |
| aPT | 2 | 2 |
| aCL + aβ2GPI + aPE | 0 | 3 |
| aCL + aβ2GPI + aPS | 0 | 3 |
| aCL + aβ2GPI + aPT | 0 | 1 |
| aCL + aPE + aPS | 1 | 3 |
| aCL + aPE + aPT | 0 | 1 |
| aCL + aPS + aPT | 0 | 1 |
| aβ2GPI + aPE + aPS | 0 | 3 |
| aβ2GPI + aPE + aPT | 0 | 1 |
| aβ2GPI + aPS + aPT | 0 | 1 |
| aPE + aPS + aPT | 0 | 1 |
| aCL + aβ2GPI + aPE + aPS | 0 | 3 |
| aCL + aβ2GPI + aPE + aPT | 0 | 1 |
| aCL + aβ2GPI + aPS + aPT | 0 | 1 |
| aβ2GPI + aPE + aPS + aPT | 0 | 1 |
| aCL + aPE + aPS + aPT | 0 | 1 |
| aCL + aβ2GPI + aPE + aPS + aPT | 0 | 1 |
APS—antiphospholipid syndrome; aPLs—antiphospholipid antibodies; aCL—anti-cardiolipin antibodies; aβ2GPI—anti-β2 glycoprotein I antibodies; aPE—anti-phosphatidylethanolamine antibodies; aPS—anti-phosphatidylserine antibodies; aPT—anti-prothrombin antibodies.